article thumbnail

Incyte wins injunction to block launch of Sun Pharma's JAK inhibitor Leqselvi

Fierce Pharma

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to launch its JAK inhibitor competitor to Eli Lilly and Incyte’s Olumiant and | Sun Pharma, which had been plotting a mid-October launch for its JAK inhibitor Leqselvi, has been slapped with in an injunction blocking the rollout of (..)

Pharma 300
article thumbnail

After temporary reprieve, Advanz Pharma's liver med Ocaliva loses marketing nod in Europe

Fierce Pharma

After a rough few months for Intercept and Advanz Pharma's Ocaliva on both sides of the Atlantic, the other shoe has dropped for the rare liver disease drug in Europe. | In turn, Intercept's liver disease drug, which is marketed by Advanz Pharma overseas, has lost its EU approval.

Marketing 300
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Acadia Pharma Sells Voucher for Speedier FDA Drug Review for $150M

MedCity News

The post Acadia Pharma Sells Voucher for Speedier FDA Drug Review for $150M appeared first on MedCity News. The biotech received the voucher last year alongside the regulatory decision that made its drug Daybue the first FDA-approved treatment for the rare disease Rett syndrome.

FDA 298
article thumbnail

Fierce Pharma Asia—AstraZeneca's China fallout; Pfizer's $1B plan in China; Incyte-Sun JAK dispute

Fierce Pharma

Sun Pharma's JAK inhibitor Leqselvi was slapped with an injunction in a lawsuit with Incyte. AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and improper collection of patient data. AstraZeneca confirmed its China president has been detained by Chinese authorities.

Pharma 318
article thumbnail

Bain Capital Broadens Its Biotech Reach With $3.3B Deal for Mitsubishi Tanabe Pharma

MedCity News

Bain Capitals buyout of Mitsubishi Tanabe Pharma brings a company with a drug portfolio and pipeline in areas such as immunology, central nervous system disorders, and metabolic disease. Deal for Mitsubishi Tanabe Pharma appeared first on MedCity News. The post Bain Capital Broadens Its Biotech Reach With $3.3B

Pharma 262
article thumbnail

AstraZeneca Turns to CSPC Pharma Again, Putting Up $110M to Start Multi-Drug R&D Pact

MedCity News

The post AstraZeneca Turns to CSPC Pharma Again, Putting Up $110M to Start Multi-Drug R&D Pact appeared first on MedCity News. The agreement follows a 2024 licensing agreement that granted AstraZeneca rights to an oral CSPC drug candidate in development for a metabolic disorder.

Pharma 235
article thumbnail

Syndax inks $350M deal with Royalty Pharma for funding to launch 2 new drugs

Fierce Pharma

To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million deal with Royalty Pharma.

Pharma 313